Does contrast agent injection during trans-catheter aortic valve implantation negatively affect kidney function?

Area of Science:

• Cardiology
• Nephrology
• Interventional Cardiology

Background:

• Trans-catheter aortic valve implantation (TAVI) is an alternative for high-risk patients with severe aortic valve stenosis.
• Elderly patients undergoing TAVI often have pre-existing renal impairment.
• TAVI involves contrast injections, posing a risk of nephrotoxicity.

Purpose of the Study:

• To assess renal function changes after TAVI.
• To determine if contrast exposure during TAVI leads to reduced kidney function.
• To evaluate the incidence of contrast-induced nephropathy post-TAVI.

Main Methods:

• Retrospective analysis of 39 patients (mean age 81.43 years) who underwent TAVI.
• Measurement of serum creatinine and estimated glomerular filtration rate (eGFR) pre-TAVI and at multiple time points post-procedure.
• Calculation of eGFR using the MDRD formula.

Main Results:

• No clinically significant reduction in renal function was observed post-TAVI (mean creatinine: 104.46 to 93.64 mmol/L; mean eGFR: 52.37 to 61.34 mL/min/1.73 m²).
• No cases of contrast-induced nephropathy were reported in the study cohort.
• Two early deaths occurred, unrelated to renal function.

Conclusions:

• TAVI, including contrast administration, does not appear to cause significant renal function decline.
• Elderly patients with severe aortic valve stenosis and renal compromise did not develop contrast-induced nephropathy after TAVI.